top of page

Bcr-Abl inhibitors
(e.g., imatinib, dasatinib, bosutinib, nilotinib, ponatinib)

imatinib

bosutinib, dasatinib**

Clinical CV examination by the hematologist AND ECG

before cancer treatment begins

Normal

Abnormal

Monitoring by the hematolgist

Cardio-oncological evaluation*

before the cancer treatment begins

nilotinib, ponatinib

Cardio-oncological evaluation*AND PAD screening by ankle brachial index measurement and Doppler of carotid/lower extremity arteries

before the cancer treatment begins

Cardio-oncology evaluation* AND home blood pressure monitoring

every 3 months for 1 year, then every 6 months during 

the Bcr-Abli therapy 

PAD screening by ankle brachial index measurement and Doppler of carotid/lower extremity arteries

every 6 months if high or very high CV risk and yearly if intermediate risk

* A cardio-oncological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, GFR calculation, ECG and trans-thoracic echocardiography (TTE). Measurements of global longitudinal strain and 3D LVEF (if feasible) are recommended with the same machine.

**TTE is recommended for baseline pulmonary pressure assessment​.

*** Estimated by the 2022 ESC guidelines

​

CV=cardiovascular; PAD=peripheral artery disease; TTE=transthoracic echocardiogram

bottom of page